Swedish Ibrance Registries Insights (SIRI)
Recruiting
Observational Study
Malignant Neoplasm of Breast
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,500 (estimated)
- Sponsor
- Pfizer · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
2. Age ≥18 years at index date
Exclusion Criteria:
There are no exclusion criteria
Contacts